ZA200703696B - Site-directed modification of FVIII - Google Patents

Site-directed modification of FVIII

Info

Publication number
ZA200703696B
ZA200703696B ZA200703696A ZA200703696A ZA200703696B ZA 200703696 B ZA200703696 B ZA 200703696B ZA 200703696 A ZA200703696 A ZA 200703696A ZA 200703696 A ZA200703696 A ZA 200703696A ZA 200703696 B ZA200703696 B ZA 200703696B
Authority
ZA
South Africa
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
ZA200703696A
Other languages
English (en)
Inventor
Clark Q Pan
John E Murphy
Mei Baison
Jonathan S Strauss
Tjandra Hendri
Chen Jianmin
Barnett Thomas
Tang Liang
Wang Deqian
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703696(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA200703696B publication Critical patent/ZA200703696B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
ZA200703696A 2004-11-12 2007-05-08 Site-directed modification of FVIII ZA200703696B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
ZA200703696B true ZA200703696B (en) 2008-08-27

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703696A ZA200703696B (en) 2004-11-12 2007-05-08 Site-directed modification of FVIII

Country Status (32)

Country Link
US (4) US7632921B2 (fr)
EP (9) EP3153181A1 (fr)
JP (5) JP2008524117A (fr)
KR (7) KR20120136413A (fr)
CN (6) CN105753968A (fr)
AU (1) AU2005304622B2 (fr)
BR (2) BRPI0517795B8 (fr)
CA (1) CA2586379C (fr)
CY (3) CY1119292T1 (fr)
DK (3) DK2371856T3 (fr)
ES (4) ES2821832T3 (fr)
FR (1) FR19C1031I2 (fr)
HK (3) HK1117875A1 (fr)
HN (1) HN2007015683A (fr)
HR (2) HRP20180481B1 (fr)
HU (5) HUE060016T2 (fr)
IL (3) IL182903A (fr)
LT (5) LT2363414T (fr)
LU (1) LUC00118I2 (fr)
MA (1) MA29663B1 (fr)
MX (2) MX2007005466A (fr)
NL (1) NL300989I2 (fr)
NO (3) NO20210454A1 (fr)
NZ (1) NZ555032A (fr)
PH (2) PH12014500352B1 (fr)
PL (3) PL2363414T3 (fr)
PT (4) PT3130601T (fr)
RU (1) RU2423380C2 (fr)
SI (4) SI3130601T1 (fr)
UA (1) UA95225C2 (fr)
WO (1) WO2006053299A2 (fr)
ZA (1) ZA200703696B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2055189A1 (fr) 2003-04-09 2009-05-06 Neose Technologies, Inc. Méthode de glycopegylation et proteines/peptides produits au moyen de ces méthodes
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7579444B2 (en) 2004-06-30 2009-08-25 Nektar Therapeutics Al, Corporation Polymer-factor IX moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
RU2423380C2 (ru) 2004-11-12 2011-07-10 БАЙЕР ХЕЛСКЕА ЛЛСи Сайт-направленная модификация fviii
EP1858543B1 (fr) 2005-01-10 2013-11-27 BioGeneriX AG Facteur de stimulation de colonie de granulocytes glycopegylé
WO2006121569A2 (fr) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
EP2049144B8 (fr) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation de peptides par l'intermédiaire de séquences de glycosylation à liaison o
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP2222329A1 (fr) * 2007-11-09 2010-09-01 Baxter International Inc. Facteur viii et facteur de von willebrand recombinés modifiés et procédé d'utilisation
RU2573587C2 (ru) * 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
KR101841870B1 (ko) 2008-05-16 2018-03-23 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
AU2009256093A1 (en) * 2008-06-04 2009-12-10 Bayer Healthcare Llc FVIII muteins for treatment of von Willebrand disease
WO2009156137A1 (fr) 2008-06-24 2009-12-30 Csl Behring Gmbh Facteur viii, facteur de von willebrand ou leurs complexes avec des durées de vies in vivo prolongées
WO2010019263A2 (fr) * 2008-08-15 2010-02-18 Genzyme Corporation Produits de construction de flt soluble pour traiter des cancers
BRPI0920259A8 (pt) * 2008-10-17 2017-09-19 Baxter Healthcare Sa Molécula de fator sanguíneo modificado, composição farmacêutica, e, métodos para preparar uma molécula de fator sanguíneo modificado e para tratar um indivíduo sofrendo de um distúrbio de coagulação sanguínea
CN102202684A (zh) * 2008-11-03 2011-09-28 拜耳医药保健有限公司 用于治疗血友病的方法
WO2010060081A1 (fr) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Procédé de détermination d’activité de facteur de coagulation sanguine pégylé dans un essai de temps de thromboplastine partielle activée à base de silice
CA2748662A1 (fr) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Conjugue proteique ayant une fraction bio-protectrice pouvant etre clivee par une endopeptidase
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
WO2010102886A1 (fr) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification du facteur viii
HUE030373T2 (en) * 2009-03-20 2017-05-29 Hanmi Science Co Ltd A method for producing a site-specific conjugate of a physiologically active polypeptide
WO2010111414A1 (fr) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Variants du facteur viii et procédés d'utilisation associés
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2772051C (fr) 2009-08-24 2020-08-18 Amunix Operating Inc. Compositions de facteur ix de coagulation et leurs procedes de fabrication et d'utilisation
US9050318B2 (en) 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011075185A1 (fr) 2009-12-18 2011-06-23 Oligasis Conjugués de polymère de phosphorylcholine à médicament ciblé
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
PL2536399T3 (pl) * 2010-02-21 2020-06-29 Bayer Healthcare Llc Sposób aktywacji i sprzęgania biocząsteczek
KR20180130008A (ko) 2010-04-15 2018-12-05 올리가시스 고분자량 쌍성이온-함유 중합체
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3508573A1 (fr) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
AU2011323236B2 (en) 2010-11-05 2017-03-30 Takeda Pharmaceutical Company Limited A new variant of antihemophilic factor VIII having increased specific activity
US20130345403A1 (en) * 2010-12-16 2013-12-26 Novo Nordisk A/S Aqueous factor viii solution
EP2654794B8 (fr) 2010-12-22 2020-04-22 Baxalta GmbH Matériels et méthodes pour la conjugaison d'un dérivé d'acide gras soluble dans l'eau à une protéine
CA2836478A1 (fr) * 2011-05-27 2012-12-06 Baxter International Inc. Proteines therapeutiques conjuguees avec des polymeres solubles dans l'eau par un groupe sulfhydryle de cysteine reduite
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
KR20140054009A (ko) 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
TWI764092B (zh) 2011-07-08 2022-05-11 美商百歐維拉提夫治療公司 因子viii嵌合及雜交多肽，及其使用方法
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
EP3693000B1 (fr) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Composés procoagulants
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
WO2014063108A1 (fr) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
EP2914293A4 (fr) 2012-10-30 2016-04-20 Biogen Ma Inc Procédés d'utilisation du polypeptide fviii
TWI690325B (zh) 2013-03-15 2020-04-11 美商百歐維拉提夫治療公司 因子viii多肽調配物
MX2015012905A (es) * 2013-03-15 2016-06-16 Bayer Healthcare Llc Formulaciones de factor viii recombinantes.
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
CN105307672B (zh) 2013-04-18 2021-01-05 诺和诺德股份有限公司 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3033098B1 (fr) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
BR112016009064A2 (pt) * 2013-10-22 2017-09-19 Inst Nat Sante Rech Med Dispositivo de emplastro cutâneo; sistema de liberação de fármaco; kit; e método de tratamento da hemofilia em um indivíduo em necessidade do mesmo
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A2 (fr) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Outils pharmacocinétiques de population et leurs utilisations
JP6778111B2 (ja) 2014-01-20 2020-10-28 オクタファルマ・アーゲー ＦＶＩＩＩ：Ｃ／ＦＶＩＩＩ：Ａｇの改良された比を有する第ＶＩＩＩ因子を製造するための方法
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015132724A1 (fr) * 2014-03-05 2015-09-11 Pfizer Inc. Mutéines améliorées du facteur viii de coagulation
US10772942B2 (en) 2014-03-24 2020-09-15 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
WO2015154090A1 (fr) * 2014-04-04 2015-10-08 Bloodworks Laboratoire ordinaire et analyse hors laboratoire de l'hémostase
SG11201608390SA (en) 2014-04-10 2016-11-29 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
EP3151852A1 (fr) 2014-06-04 2017-04-12 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016142288A1 (fr) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Facteur von willebrand modifié présentant une demi-vie améliorée
DK3297656T3 (da) 2015-05-22 2020-03-09 CSL Behring Lengnau AG Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
EP4089109A3 (fr) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Procédés de préparation du facteur willebrand modifié
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
CN109689683A (zh) * 2016-06-24 2019-04-26 财团法人牧岩生命科学研究所 重组单链fvⅲ及其化学缀合物
AU2017358861B2 (en) 2016-11-11 2022-02-17 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for treating hemophilia
ES2908008T3 (es) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Polipéptidos truncados del Factor de von Willebrand para su administración extravascular en el tratamiento o profilaxis de un trastorno de la coagulación sanguínea
MX2019005693A (es) 2016-11-16 2019-08-14 Bayer Healthcare Llc Factor viii direccionado a los globulos rojos y metodo para su uso.
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
US20190381149A1 (en) 2016-12-02 2019-12-19 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MX2019009063A (es) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (fr) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York Compositions de conjugués d'inhibiteurs de caspase de pénétration cellulaire à concentration élevée et procédés associés
CN114828870A (zh) * 2019-12-06 2022-07-29 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (fr) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Protéines à activité de facteur VIII, procédé pour leur production utilisant des cellules modifiées par génie génétique et compositions pharmaceutiques les contenant
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
ATE198277T1 (de) 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (fr) 1994-11-09 1996-12-27 Offord Robin E Polymeres fonctionnalises destines a une ligation dirigee
CA2198111C (fr) * 1995-06-21 2000-01-11 James Patrick Phillips Methode et antenne realisant un diagramme de rayonnement equidirectif
WO1997003195A1 (fr) 1995-07-11 1997-01-30 Chiron Corporation Nouveaux analogues polypeptidiques de facteur viii:c ayant des sites de protease modifies
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
DE69736780T2 (de) * 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
CA2225189C (fr) 1997-03-06 2010-05-25 Queen's University At Kingston Gene et proteine du facteur viii du chien et methodes d'utilisation
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2001520198A (ja) * 1997-10-17 2001-10-30 ハーベスト・テクノロジーズ・コーポレイション 血小板富有血漿からの成長因子富有化フィブリノーゲン濃縮物の調製
EP0922446A1 (fr) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Préparation des conjugués du GRF-PEG par un méthode en solution spécifique à un site
CA2329768C (fr) 1998-04-27 2008-06-10 Opperbas Holding B.V. Composition pharmaceutique a base de facteur viii et de liposomes neutres
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
WO2000028021A1 (fr) 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Polypeptide du facteur viii a activite de facteur viii:c
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
EP1144613B2 (fr) 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Techniques permettant de produire des proteines contenant des residus cysteine libres
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
BR0208203A (pt) * 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
WO2002096454A1 (fr) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Molecules recombinees avec immunogenicite reduite, procedes et intermediaires permettant d'obtenir ces molecules, et utilisation de ces molecules dans des compositions pharmaceutiques et des outils diagnostiques
WO2002098454A2 (fr) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Molecules recombinees a immunogenicite reduite, procedes et produits intermediaires pour les obtenir et leur utilisation dans des compositions pharmaceutiques et des outils diagnostiques
WO2002103024A2 (fr) 2001-06-14 2002-12-27 The Scripps Research Institute Proteines stabilisees avec des liaisons disulfure genetiquement modifiees
AU2002337901B2 (en) 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
RU2004133761A (ru) 2002-04-18 2005-07-10 Мерк Патент ГмбХ (DE) Модифицированный фактор viii
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
AU2003300139B2 (en) 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
DE602004029646D1 (en) 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
EP1596887B1 (fr) * 2003-02-26 2022-03-23 Nektar Therapeutics Conjugues de groupe fonctionnel a facteur polymerique viii
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2004101600A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
EP1626741A2 (fr) 2003-05-23 2006-02-22 Nektar Therapeutics Al, Corporation Derives polymeres ayant des agencements d'atomes particuliers
EP1502921A1 (fr) 2003-07-29 2005-02-02 ZLB Behring GmbH Mutants du Facteur VIII (FVIII) humain recombinants ayant une meilleure stabilité
WO2005046583A2 (fr) 2003-10-30 2005-05-26 Emory University Facteur fviii modifie presentant une immunogenicite reduite par mutagenese d'epitopes a2 et c2
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (fr) 2003-12-03 2010-04-07 University of Rochester Facteur viii recombine presentant une activite specifique amelioree
WO2006027111A1 (fr) 2004-09-06 2006-03-16 Zlb Behring Gmbh Facteur viii de coagulation modifie presentant une meilleure stabilite
RU2423380C2 (ru) 2004-11-12 2011-07-10 БАЙЕР ХЕЛСКЕА ЛЛСи Сайт-направленная модификация fviii
EP1871801A2 (fr) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Analogues du fviii de coagulation sanguine
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII

Also Published As

Publication number Publication date
MX350293B (es) 2017-09-04
KR20140019489A (ko) 2014-02-14
EP1824988A2 (fr) 2007-08-29
SI3130601T1 (sl) 2020-11-30
IL234433B (en) 2019-11-28
KR20140091618A (ko) 2014-07-21
CN105148287A (zh) 2015-12-16
JP2017105773A (ja) 2017-06-15
PT2363414T (pt) 2022-08-04
US20130274445A1 (en) 2013-10-17
HRP20180481A2 (hr) 2018-06-29
CN105148287B (zh) 2019-07-09
UA95225C2 (ru) 2011-07-25
EP2772500B1 (fr) 2019-12-25
ES2633916T3 (es) 2017-09-26
RU2423380C2 (ru) 2011-07-10
BR122016022033B1 (pt) 2021-03-02
JP6487895B2 (ja) 2019-03-20
EP1824988B1 (fr) 2017-04-19
KR101654011B1 (ko) 2016-09-05
PH12019501613A1 (en) 2020-09-14
BRPI0517795B1 (pt) 2020-03-31
US20060115876A1 (en) 2006-06-01
KR101483917B1 (ko) 2015-01-16
HUE033776T2 (en) 2018-01-29
PH12014500352A1 (en) 2015-07-20
IL232540A (en) 2017-08-31
JP2008524117A (ja) 2008-07-10
CN103214569B (zh) 2016-12-28
KR20180110192A (ko) 2018-10-08
EP3243833B1 (fr) 2020-06-17
CN101124331A (zh) 2008-02-13
CN105753968A (zh) 2016-07-13
HK1218718A1 (zh) 2017-03-10
EP3130601B1 (fr) 2020-07-15
US9096656B2 (en) 2015-08-04
NO344606B1 (no) 2020-02-10
JP2017101028A (ja) 2017-06-08
EP2772500A1 (fr) 2014-09-03
SI2371856T1 (sl) 2022-09-30
EP3323829A1 (fr) 2018-05-23
LT1824988T (lt) 2017-10-25
LTC1824988I2 (lt) 2021-02-25
CN107082806A (zh) 2017-08-22
HK1182121A1 (en) 2013-11-22
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
HRP20180481B1 (hr) 2022-02-18
EP2371856B1 (fr) 2022-05-18
KR101468345B1 (ko) 2014-12-03
EP2363414A3 (fr) 2012-03-21
LTPA2019509I1 (lt) 2019-08-26
EP2363414A2 (fr) 2011-09-07
NL300989I1 (nl) 2019-05-22
MX2007005466A (es) 2007-10-19
HRP20070268A2 (en) 2007-09-30
BR122016022033B8 (pt) 2021-05-25
AU2005304622A1 (en) 2006-05-18
LT2363414T (lt) 2022-10-25
BRPI0517795B8 (pt) 2021-05-25
CN103102406B (zh) 2015-05-27
ES2821832T3 (es) 2021-04-27
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
KR101243564B1 (ko) 2013-03-27
HUS1900026I1 (hu) 2022-04-28
CN103102406A (zh) 2013-05-15
EP3153181A1 (fr) 2017-04-12
NZ555032A (en) 2010-02-26
CY1123384T1 (el) 2021-12-31
PL1824988T3 (pl) 2018-01-31
BRPI0517795A (pt) 2008-10-21
CA2586379A1 (fr) 2006-05-18
US7632921B2 (en) 2009-12-15
KR20130036780A (ko) 2013-04-12
DK2363414T3 (da) 2022-08-08
LUC00118I1 (fr) 2019-05-13
PT1824988T (pt) 2017-07-21
HUE050542T2 (hu) 2020-12-28
WO2006053299A3 (fr) 2006-08-24
FR19C1031I2 (fr) 2020-06-05
IL182903A (en) 2014-09-30
US20160051633A1 (en) 2016-02-25
US9364520B2 (en) 2016-06-14
HK1117875A1 (en) 2009-01-23
LT3130601T (lt) 2020-09-10
HN2007015683A (es) 2011-07-11
NO20200044A1 (no) 2007-06-27
CY2019024I2 (el) 2019-11-27
DK1824988T3 (en) 2017-08-07
HUE059193T2 (hu) 2022-10-28
RU2007121517A (ru) 2008-12-20
KR101904630B1 (ko) 2018-10-04
NL300989I2 (nl) 2019-11-28
DK2371856T3 (en) 2022-08-08
FR19C1031I1 (fr) 2019-06-28
EP3243833A1 (fr) 2017-11-15
JP6559642B2 (ja) 2019-08-14
AU2005304622B2 (en) 2012-03-29
CY1119292T1 (el) 2018-02-14
JP6109523B2 (ja) 2017-04-05
PT2371856T (pt) 2022-08-12
KR20160105928A (ko) 2016-09-07
CN103214569A (zh) 2013-07-24
LUC00118I2 (fr) 2019-12-27
JP2013067621A (ja) 2013-04-18
HUE060016T2 (hu) 2023-01-28
WO2006053299A2 (fr) 2006-05-18
NO20072997L (no) 2007-06-27
HRP20070268B1 (hr) 2018-04-20
EP2371856A2 (fr) 2011-10-05
PH12014500352B1 (en) 2015-07-20
EP1824988A4 (fr) 2008-12-31
US20100081615A1 (en) 2010-04-01
LT2371856T (lt) 2022-08-25
BRPI0517795A8 (pt) 2018-12-26
CY2019024I1 (el) 2019-11-27
EP3130601A1 (fr) 2017-02-15
IL182903A0 (en) 2007-08-19
JP2015134780A (ja) 2015-07-27
SI1824988T1 (sl) 2017-11-30
KR20120136413A (ko) 2012-12-18
PT3130601T (pt) 2020-10-01
EP2363414B1 (fr) 2022-05-18
PL2363414T3 (pl) 2022-09-05
EP3323829B1 (fr) 2020-07-15
CA2586379C (fr) 2012-04-03
ES2930143T3 (es) 2022-12-07
IL232540A0 (en) 2014-06-30
EP2371856A3 (fr) 2012-03-14
EP3243834A1 (fr) 2017-11-15
PL2371856T3 (pl) 2022-08-22
NO345800B1 (no) 2021-08-09
MA29663B1 (fr) 2008-08-01
ES2930159T3 (es) 2022-12-07
CN101124331B (zh) 2013-04-24

Similar Documents

Publication Publication Date Title
HUS1900026I1 (hu) FVIII helyspecifikus módosítása
EP1785131A4 (fr) Preparation externe de type s/o
GB0524619D0 (en) Improved osteotome
EP1773871A4 (fr) Composés associés au facteur de différenciation tissulaire et leurs analogues
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EP1731147A4 (fr) Préparation externe
PL1720633T3 (pl) Płuczka wieżowa gazu
GB0428026D0 (en) Infant aid
AU300055S (en) Scrubber
GB2416051B (en) Selection of component
ZA200508325B (en) Manufacture of kerbstones
GB0421155D0 (en) Piece of mind plan
GB0415217D0 (en) Compounds and uses thereof
GB0412872D0 (en) Novel structures
PL369353A1 (pl) Zestaw elementów budowlanych
AU157294S (en) External cornice corner member
TWM275831U (en) Improved structure of cinerary urn